ELLAGRIN / SHUTTERSTOCK.COM
It is unclear whether the so-called new therapeutic entities are qualified to be patented under current Mexican IP laws. Soledad Betanzos-Lara of Goodrich, Riquelme y Asociados examines the current landscape.
If you have already subscribed please login.
If you have any technical issues please email tech support.
NTEs, patent, generics, New therapeutic entities, supergenerics
